Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 144.68M | 17.88M | 294.69M | 214.21M | 284.22M |
| Total Depreciation and Amortization | 1.22M | 1.29M | 1.17M | 1.20M | 1.28M |
| Total Amortization of Deferred Charges | 8.27M | 7.73M | 7.67M | 7.54M | 7.84M |
| Total Other Non-Cash Items | -286.78M | -199.99M | -420.48M | -360.43M | -422.21M |
| Change in Net Operating Assets | 818.69M | 901.55M | 835.18M | 964.64M | 831.48M |
| Cash from Operations | 686.08M | 728.46M | 718.23M | 827.15M | 702.62M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | -226.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -285.66M | -229.72M | -477.87M | -847.80M | -958.09M |
| Cash from Investing | -285.66M | -229.72M | -477.87M | -847.80M | -958.31M |
| Total Debt Issued | 50.00M | -- | -- | 0.00 | 3.23B |
| Total Debt Repaid | -430.00M | -- | -- | 0.00 | -2.28B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -86.34M | -44.64M | -50.10M | -80.54M | -146.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -105.12M | -104.92M | -104.49M | -94.34M | -95.31M |
| Other Financing Activities | -127.29M | -123.59M | -118.08M | -124.72M | -149.94M |
| Cash from Financing | -698.74M | -273.15M | -272.67M | -299.60M | 562.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -298.33M | 225.59M | -32.30M | -320.25M | 307.04M |